Trial Search Results

Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer

This trial will evaluate Hu5F9-G4 in combination with cetuximab. Hu5F9-G4 is a monoclonal antibody which is designed to block a protein called CD47, which is widely expressed on human cancer cells. Blocking CD47 with Hu5F9-G4 may enable the body's immune system to find and destroy the cancer cells. Cetuximab is a monoclonal antibody drug that is used for treatment of certain types of colorectal cancer as well as head and neck cancer.

The major aims of the study are: (Phase 1b) to define the safety profile and to determine a recommended Phase 2 dose for Hu5F9-G4 in combination with cetuximab, and (Phase 2) to evaluate the objective response rate of Hu5F9-G4 in combination with cetuximab in patients with advanced colorectal cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Gilead Sciences

Collaborator: California Institute for Regenerative Medicine (CIRM)

Stanford Investigator(s):


  • Drug: Hu5F9-G4
  • Drug: Cetuximab


Phase 1/Phase 2


Inclusion Criteria:

   - Histological Diagnosis

      - Phase 1b only: Advanced solid malignancy with an emphasis on colorectal, head and
      neck, breast, pancreatic and ovarian cancers who have been treated with at least
      one regimen of prior systemic therapy, or who refuse systemic therapy, and for
      which there is no curative therapy available.

      - Phase 2:

   - KRAS Mutant CRC: Advanced KRAS mutant CRC who have progressed or are ineligible for
   both irinotecan and oxaliplatin based chemotherapy

   - KRAS Wild Type CRC: Advanced KRAS wild type CRC who have progressed or are ineligible
   for both irinotecan and oxaliplatin based chemotherapy and who are relapsed or
   refractory to at least 1 prior systemic therapy that included an anti-EGFR antibody,
   such as cetuximab, panitumumab or others.

   - Adequate performance status and hematological, liver, and kidney function

   - Phase 2 only: Willing to consent to 1 mandatory pre-treatment and 1 on-treatment tumor

Exclusion Criteria:

   - Active brain metastases

   - Prior treatment with CD47 or signal regulatory protein alpha (SIRPĪ±) targeting agents.

   - Phase 2 only: second malignancy within the last 3 years.

   - Known active or chronic hepatitis B or C infection or HIV

   - Pregnancy or active breastfeeding

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Flordeliza Mendoza
Not Recruiting